SynthesisAmerican journal of clinical dermatology2021
Psychosocial Effects of Vitiligo: A Systematic Literature Review.
Synthesis in American journal of clinical dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 4 syntheses or guidelines pooled it, 232 citations in OpenAlex.
- Cross-Cultural Beliefs and Stigmatization in Vitiligo: A Systematic Review.Journal of cosmetic dermatology · 2026Pooled it
- Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study.Journal of cosmetic dermatology · 2025Pooled it
- Global clinicoepidemiological pattern of childhood vitiligo: a systematic review and meta-analysis.BMJ paediatrics open · 2023Pooled it
- The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.JAMA dermatology · 2025Trial
- The Efficacy of 308-nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo.Journal of cosmetic dermatology · 2025Trial
- [Vitiligo in Germany : A claims data analysis on prevalence, comorbidity, and treatment patterns].Dermatologie (Heidelberg, Germany) · 2026Article
- Methodological strategies for mappingWorld journal of methodology · 2026Review
- Current Management and Emerging Therapies for Pediatric Vitiligo: A Narrative Review.Paediatric drugs · 2026Review
- Exploring and Comparing the Psychosocial Impacts of Vitiligo on a Broader Scale: An International Survey via the Use of Social Media.The Australasian journal of dermatology · 2026Article
- Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- [Medical care situation of people with vitiligo : A pilot and feasibility study on guideline-oriented management in German dermatology practices].Dermatologie (Heidelberg, Germany) · 2026Observational
- Interleukin 32 Exacerbates Vitiligo by Promoting Inflammation and Oxidative Stress-induced Injury in Melanocytes.Inflammation · 2026Article
- Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo.Dermatology and therapy · 2026Article
- Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.JAMA dermatology · 2026Article
- Psychiatric Comorbidity in Hidradenitis Suppurativa-A Large-Scale Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool.Current oncology (Toronto, Ont.) · 2026Article
- Quality of life impairment in vitiligo: A comprehensive review of psychosocial and clinical determinants.The Journal of international medical research · 2026Review
- Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.Dermatology and therapy · 2026Article
- Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus.Dermatology and therapy · 2026Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with vitiligo experience reduced quality of life.
objectiveTo comprehensively describe the available evidence for psychosocial burden in vitiligo.
methodsA systematic review of observational studies and clinical trials identified using PubMed, EMBASE, Scopus, and the Cochrane databases was performed through 1 March, 2021, to assess psychosocial comorbidities in vitiligo. Two independent reviewers performed an assessment of articles and extracted data for qualitative synthesis.
resultsIncluded studies (N = 168) were published between 1979 and 1 March, 2021; 72.6% were published since 2010. Disorders including or related to depression (41 studies, 0.1-62.3%) and anxiety (20 studies, 1.9-67.9%) were the most commonly reported. The most prevalent psychosocial comorbidities were feelings of stigmatization (eight studies, 17.3-100%), adjustment disorders (12 studies, 4-93.9%), sleep disturbance (seven studies, 4.6-89.0%), relationship difficulties including sexual dysfunction (ten studies, 2.0-81.8%), and avoidance or restriction behavior (12.5-76%). The prevalence of most psychosocial comorbidities was significantly higher vs healthy individuals. Factors associated with a significantly higher burden included female sex, visible or genital lesions, age < 30 years (particularly adolescents), and greater body surface area involvement, among others. The most commonly reported patient coping strategy was lesion concealment. LIMITATIONS: Available studies were heterogeneous and often had limited details; additionally, publication bias is possible.
conclusionsThe results of this systematic review show that vitiligo greatly affects psychosocial well-being. The extent of psychosocial comorbidities supports the use of multidisciplinary treatment strategies and education to address the vitiligo-associated burden of disease. PROTOCOL REGISTRATION: PROSPERO (CRD42020162223).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.